Aisling Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-288,571
| Closed | -$46.2K | – | 14 |
|
|
2024
Q4 | $46.2K | Hold |
288,571
| – | – | 0.02% | 15 |
|
|
2024
Q3 | $66.4K | Hold |
288,571
| – | – | 0.03% | 16 |
|
|
2024
Q2 | $157K | Hold |
288,571
| – | – | 0.07% | 15 |
|
|
2024
Q1 | $294K | Hold |
288,571
| – | – | 0.1% | 16 |
|
|
2023
Q4 | $164K | Hold |
288,571
| – | – | 0.05% | 15 |
|
|
2023
Q3 | $300K | Hold |
288,571
| – | – | 0.12% | 16 |
|
|
2023
Q2 | $407K | Hold |
288,571
| – | – | 0.2% | 15 |
|
|
2023
Q1 | $459K | Hold |
288,571
| – | – | 0.22% | 14 |
|
|
2022
Q4 | $421K | Hold |
288,571
| – | – | 0.28% | 15 |
|
|
2022
Q3 | $1.23M | Hold |
288,571
| – | – | 0.82% | 12 |
|
|
2022
Q2 | $1.12M | Hold |
288,571
| – | – | 0.8% | 13 |
|
|
2022
Q1 | $1.37M | Hold |
288,571
| – | – | 0.74% | 16 |
|
|
2021
Q4 | $1.05M | Hold |
288,571
| – | – | 0.37% | 20 |
|
|
2021
Q3 | $2.31M | Hold |
288,571
| – | – | 0.46% | 19 |
|
|
2021
Q2 | $3.27M | Buy |
+288,571
| New | +$2.9M | 0.52% | 19 |
|
|
2021
Q1 | – | Sell |
-288,571
| Closed | -$2.01M | – | 16 |
|
|
2020
Q4 | $2.01M | Hold |
288,571
| – | – | 0.35% | 14 |
|
|
2020
Q3 | $1.26M | Hold |
288,571
| – | – | 0.4% | 14 |
|
|
2020
Q2 | $2.66M | Hold |
288,571
| – | – | 1.02% | 9 |
|
|
2020
Q1 | $4.19M | Hold |
288,571
| – | – | 1.83% | 8 |
|
|
2019
Q4 | $3.41M | Hold |
288,571
| – | – | 1.31% | 9 |
|
|
2019
Q3 | $7.27M | Buy |
288,571
+71,428
| +33% | +$2.06M | 3.79% | 7 |
|
|
2019
Q2 | $5.55M | Hold |
217,143
| – | – | 2.37% | 10 |
|
|
2019
Q1 | $9.23M | Buy |
217,143
+142,857
| +192% | +$3.24M | 7.03% | 7 |
|
|
2018
Q4 | $1.09M | Buy |
+74,286
| New | +$3.03M | 1.15% | 12 |
|
Other funds holding VIRX
XT
UCFA
WA
BBA
RM